Alpha-synuclein

Alpha-synuclein

New Alpha-Synuclein Therapy Begins Clinical Trial

Monday, 1 April 2019

The Parkinson’s therapeutic pipeline continues to grow as another therapy targeting the protein alpha-synuclein begins human studies. Earlier this month, BioArctic announced that it, along with its partner AbbVie, has begun clinical trials joining seven other alpha-synuclein therapies already being tested by…

Parkinson's research

Update on Alpha-synuclein Therapies in Clinical Trials

Monday, 17 July 2017

Last week biotech Prothena announced the first participant has enrolled in its PASADENA study, a Phase II trial of its anti-alpha-synuclein antibody therapy. Five companies have therapies in clinical trials targeting alpha-synuclein, the protein that clumps in the cells of people with…

Parkinson's Reseach at university of Queensland

Alpha-synuclein Research Progress for Parkinson’s

Saturday, 1 July 2017

As researchers search for a therapy to slow or stop Parkinson’s disease (PD) progression, alpha-synuclein has emerged as a leading target. This protein clumps in the brains of nearly everyone with Parkinson’s and it’s the primary component of Lewy bodies,…

Dr Richard Gordon research into Parkinson's disease

UQ study seeks Parkinson’s treatment in existing drug

Saturday, 1 April 2017

Shake It Up Australia together with The Michael J. Fox Foundation is excited to be funding a new research project at the University of Queensland.  Their research team will investigate the potential of repurposing an existing blood pressure drug to…

Blood test may confirm parkinsons diagnosis

Alpha-synuclein Antibody moves a step closer

Monday, 14 November 2016

Therapeutic projects against top target protein alpha-synuclein continue to march through clinical testing and closer to patient hands. Yesterday biotechnology company Prothena announced results from its Phase Ib trial of PRX002, an antibody under investigation as a treatment to slow…

Vaccine for Parkinson’s Reports Positive Results from Boost Study

Monday, 12 September 2016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. Today the company announced its “boost” follow-up study — funded with a $1.04 million grant from The Michael J. Fox Foundation…

Another Piece of the Alpha-synuclein Puzzle Revealed

Monday, 25 July 2016

Research on alpha-synuclein, a lead target for therapy to slow or stop Parkinson’s and potential marker of disease progression, is quickly advancing, and scientists are learning more about this protein’s role in Parkinson’s disease (PD). Recently, researchers discovered how this…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Measuring Parkinson’s Protein throughout Body

Saturday, 19 March 2016

Alpha-synuclein — the protein that clumps in brain cells of people with Parkinson’s — is not only a therapeutic target but also may be a measure of disease. Today, The Michael J. Fox Foundation (MJFF) launched the Systemic Synuclein Sampling Study…

Who’s to Blame? Finding Toxic Alpha-synuclein

Monday, 28 April 2014

Alpha-synuclein shoulders a lot of blame in Parkinson’s disease (PD). This protein clumps in the cells of all Parkinson’s patients, leading to cell dysfunction and cell death. But not all alpha-synuclein may be bad. Scientists do not yet know the…

News in Context: Parkinson’s Biomarker May Be Only Skin Deep

News in Context: Parkinson’s Biomarker May Be Only Skin Deep

Monday, 13 January 2014

Recently researchers from Beth Israel Deaconess Medical Center in Boston published a paper in Neurology on their findings that alpha-synuclein levels in nerve cells found in the skin differed between Parkinson’s patients and healthy controls. We talked to Roy Freeman,…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Finding the Origin of a Toxic Species

Wednesday, 11 September 2013

Since it’s discovery in 1997, it has become increasingly clear that the protein alpha-synuclein is closely associated with Parkinson’s disease (PD). But while it’s known that all people with PD experience a build-up of alpha-synuclein in their brains (called Lewy Bodies), it’s…